Search
Now showing items 81-90 of 107
The tail wagging the dog: the diagnostic accuracy of first rank symptoms COMMENTARY ON… COCHRANE CORNER
(2019-10)
Outcomes for people with schizophrenia are improved by expedient diagnosis and specific treatment. ICD-11 and DSM-5 have reduced the importance of Schneider's first rank symptoms (FRS) in the diagnosis of schizophrenia; ...
Is adjunctive CBT really effective for schizophrenia?
(2019-09)
Although antipsychotic medication remains the
mainstay of treatment for schizophrenia, medications
alone are not always successful. Cognitive–
behavioural therapy (CBT) is recommended as an
adjunct to pharmacological ...
Valproate in dementia: time to move on? Commentary on…Cochrane Corner
(2019-02)
Baillon et al ’s Cochrane review included 430 participants with agitation in dementia from five randomised controlled trials. Overall, the reviewers
found that valproate was no better than placebo
for the treatment of ...
S59 Reduction in fatalities following introduction of an initial home oxygen risk mitigation form (IHORM) for all new patients on home oxygen in England and Wales
(2019-11)
Introduction Home Oxygen can be ordered by any registered Healthcare professional in England and Wales. There are approximately 130,000 patients on Home Oxygen at any time.
No specialist training is required to request ...
Signal variance-based collateral index in DSC perfusion: A novel method to assess leptomeningeal collateralization in acute ischaemic stroke
(2019-02)
As a determinant of the progression rate of the ischaemic process in acute large-vessel stroke, the degree of collateralization is a strong predictor of the clinical outcome after reperfusion therapy and may influence ...
CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice
(2019-08)
Neuroinflammation and microglial activation are significant processes in Alzheimer’s disease pathology. Recent genome-wide association studies have highlighted multiple immune-related genes in association with Alzheimer’s ...
Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease A Randomized Clinical Trial
(2019-11)
IMPORTANCE There are no disease-modifying treatments for Alzheimer disease (AD), the
most common cause of dementia. Minocycline is anti-inflammatory, protects against the toxic
effects of β-amyloid in vitro and in animal ...
The Oxford study of Calcium channel Antagonism, Cognition, Mood instability and Sleep (OxCaMS): study protocol for a randomised controlled, experimental medicine study
(2019-02)
Background:
The discovery that voltage-gated calcium channel genes such as CACNA1C are part of the aetiology of psychiatric disorders has rekindled interest in the therapeutic potential of L-type calcium channel (LTCC) ...
Impulse control disorders in Parkinson disease and RBD
(2019-10)
Objective
To describe the prevalence, natural history, and risk factors for impulse control behaviors
(ICBs) among people with Parkinson disease (PD), those with REM sleep behavior disorder
(RBD), and controls.
Metho ...
Effects of ketamine treatment on suicidal ideation: a qualitative study of patients’ accounts following treatment for depression in a UK ketamine clinic
(2019-08)
Objective It is recognised that ketamine treatment can
reduce suicidal ideation (SI) in people with depression, at
least in the short term. However, information is lacking on
patients’ perspectives on such effects. ...